---
title: "argenx (ARGX) stock news, pipeline, cash and catalysts"
url: "https://aibio.space/companies/argenx/"
publisher: "aibio.space (Biotech Investor Relations News)"
summary: "argenx news for investors: argenx sells Vyvgart, an antibody drug that lowers disease-causing IgG antibodies, for myasthenia gravis and CIDP, and is testing…"
---

Desk view · Opinion · Updated Oct 22, 2026

## argenx needs a second drug to match its first

argenx has built a profitable business on one mechanism and keeps adding labels, but it depends on a single drug and 2026 showed where that drug stops working. December's empasiprubart readout is the clearest test of whether the company can grow beyond Vyvgart.

Read the full desk view

aibio.space Investor Rank · Opinion

**8** /10 Positive view

Profitable with Vyvgart sales up 54%, but all revenue comes from one drug, 2026 brought two trial failures, and empasiprubart has yet to read out.

- **Technology**: 2/2

- **Odds**: 1/2

- **Balance sheet**: 2/2

- **Risk**: 1/2

- **Momentum**: 2/2

Opinion only. The Investor Rank is aibio.space's opinion of the company's business position, drawn from the public sources on this page. It is not a recommendation to buy, sell or hold any security and it is not investment advice. It does not consider the share price, valuation or your circumstances, and it can change at any time. Payments from companies never affect it. [How the rank works](https://aibio.space/disclosures/#rank).

- **Technology**: **Proven FcRn blocker.** Vyvgart is approved in generalized myasthenia gravis of all serotypes and CIDP, with $1.72 billion in Q3 sales.

- **Odds**: **Strong but not perfect.** Three trial wins in 2026 sit beside a futility stop in Sjögren's and a dermatomyositis miss.

- **Balance sheet**: **Profitable with $3.7 billion.** Q3 net income was $506 million after the $2.2 billion Forte deal reduced cash.

- **Main risk**: **One-drug dependence.** Every dollar of revenue comes from efgartigimod, and growth slowed from 63% to 54% this year.

- **Watch next**: **EMPASSION in December.** It is the first phase 3 readout for empasiprubart, argenx's second molecule.

## Top news on argenx

## Dates

**December 2026**
Topline phase 3 EMPASSION results for empasiprubart in multifocal motor neuropathy [Source](https://www.sec.gov/Archives/edgar/data/0001697862/000169786226000034/a02earningspressreleaseq3.htm)

**By year-end 2026**
sBLA submission for Vyvgart Hytrulo in IMNM [Source](https://www.sec.gov/Archives/edgar/data/0001697862/000169786226000034/a02earningspressreleaseq3.htm)

**February 2027**
FDA decision on pediatric generalized myasthenia gravis [Source](https://www.sec.gov/Archives/edgar/data/0001697862/000169786226000034/a02earningspressreleaseq3.htm)

**H1 2027**
Topline phase 3 ADVANCE-NEXT results in primary ITP [Source](https://www.sec.gov/Archives/edgar/data/0001697862/000169786226000034/a02earningspressreleaseq3.htm)

**H2 2027**
Topline phase 3 EMVIGORATE and EMNERGIZE results for empasiprubart in CIDP [Source](https://www.sec.gov/Archives/edgar/data/0001697862/000169786226000034/a02earningspressreleaseq3.htm)

## The money

$3.7 billion in cash, cash equivalents and current financial assets at September 30, 2026 (Q3), after paying about $2.1 billion for Forte Biosciences net of acquired cash. The company is profitable; 2026 combined R&D and SG&A guided at about $4 billion. [Source](https://www.sec.gov/Archives/edgar/data/0001697862/000169786226000034/a02earningspressreleaseq3.htm)

Q3 2026 Vyvgart product net sales $1.721 billion, up 54% year over year and 13% from Q2. [Source](https://www.sec.gov/Archives/edgar/data/0001697862/000169786226000034/a02earningspressreleaseq3.htm)

## Risks on the record

- All product revenue comes from one drug, efgartigimod (Vyvgart and Vyvgart Hytrulo). [Source](https://www.sec.gov/Archives/edgar/data/0001697862/000169786226000034/a02earningspressreleaseq3.htm)
- The phase 3 UNITY trial in Sjögren's disease was stopped for futility in October 2026, and ALKIVIA's dermatomyositis group missed statistical significance. [Source](https://www.sec.gov/Archives/edgar/data/0001697862/000110465926114491/tm2627263d1_ex99-2.htm)
- The company lists integrating Forte, competition, tariffs and reimbursement rules among its forward-looking risks. [Source](https://www.sec.gov/Archives/edgar/data/0001697862/000169786226000034/argxq326.htm)

## Questions investors ask

### What is aibio.space's Investor Rank for argenx?

8 out of 10, our positive view. Profitable with Vyvgart sales up 54%, but all revenue comes from one drug, 2026 brought two trial failures, and empasiprubart has yet to read out. This is opinion only, not a recommendation to buy, sell or hold, and it does not consider the share price or valuation. [Source](https://aibio.space/disclosures/#rank)

### How much did argenx Vyvgart sell in Q3 2026?

Vyvgart product net sales were $1.721 billion in the third quarter of 2026, up 54% from a year earlier and 13% from the second quarter. argenx reported the results on October 22, 2026. [Source](https://www.sec.gov/Archives/edgar/data/0001697862/000169786226000034/a02earningspressreleaseq3.htm)

### Why did argenx stop the UNITY Sjögren's trial?

An independent data monitoring committee recommended stopping the phase 3 UNITY study for futility at an interim analysis, concluding it could not meet its primary endpoint of change in clinESSDAI at week 48. No new safety signals were seen. [Source](https://www.sec.gov/Archives/edgar/data/0001697862/000110465926114491/tm2627263d1_ex99-2.htm)

### How much did argenx pay for Forte Biosciences?

argenx agreed to pay $77 per share in cash, about $2.2 billion in equity value, funded from cash on hand. The deal closed in August 2026 and added the anti-CD122 antibody FB102. [Source](https://www.pharmexec.com/view/argenx-acquires-forte-biosciences-2-billion)

### Is Vyvgart approved for seronegative myasthenia gravis?

Yes. On May 8, 2026, the FDA expanded Vyvgart and Vyvgart Hytrulo to adults with generalized myasthenia gravis of all serotypes, including anti-MuSK, anti-LRP4 and triple seronegative patients, based on the ADAPT SERON trial. [Source](https://www.vfb.be/Media/Default/pdf/argenx-announces-u-s-fda-approval-expanding.pdf)

### When is argenx's next major data readout?

Topline phase 3 EMPASSION results for empasiprubart in multifocal motor neuropathy are expected in December 2026. ADVANCE-NEXT in primary ITP follows in the first half of 2027. [Source](https://www.sec.gov/Archives/edgar/data/0001697862/000169786226000034/a02earningspressreleaseq3.htm)

### Is argenx a smaller reporting company?

SEC records list argenx SE's filer category as: Large accelerated filer. Source

### Where is argenx headquartered?

SEC records list its business address as INDUSTRIEPARK ZWIJNAARDE 7, ZWIJNAARDE. Source

### When does argenx's fiscal year end?

argenx SE's fiscal year ends on December 31, per SEC records. Source

### What did argenx last file with the SEC?

Its most recent filing in our record is a 6-K filed 2026-10-22. All of its filings are on SEC EDGAR. [Source](https://www.sec.gov/Archives/edgar/data/1697862/000169786226000034/a01coverpageforsecfilingq3.htm)

### What was argenx called before?

SEC records list these former names: argenx N.V. Source

### What industry is argenx in?

Its SEC industry code (SIC 2836) is Biological Products, (No Diagnostic Substances). Source

## Legal and investor matters

Checked against argenx filings and press releases. Allegations are allegations; nothing here is a finding of fault. Reviewed Oct 25, 2026.

argenx's 20-F filed 2026-03-19 (Item 8.A, Legal proceedings) says that during the previous 12 months there were no legal, governmental or arbitration proceedings that may have, or have had in the recent past, significant effects on argenx or the Group's financial position or profitability. [Source](https://www.sec.gov/Archives/edgar/data/1697862/000169786226000032/argx-20251231.htm)

1. 2026-08-27 Other argenx completes acquisition of Forte Biosciences argenx said on 2026-08-27 that it completed its cash tender offer and merger for Forte Biosciences at $77.00 per share. As of the offer expiration on 2026-08-26, 19,894,879 Forte shares had been tendered, which with shares argenx and its affiliates already owned was about 87.13% of the outstanding shares. Forte became a wholly owned subsidiary and its stock stopped trading on Nasdaq. [argenx Form 6-K (press release)](https://www.sec.gov/Archives/edgar/data/1697862/000114036126034700/ef20081196_ex99-1.htm)
2. 2026-07-27 Other argenx agrees to buy Forte Biosciences for about $2.2 billion in cash argenx and Forte Biosciences announced on 2026-07-27 a definitive agreement under which argenx would acquire Forte for $77 per share in cash, a total equity value of about $2.2 billion. argenx said the deal has no financing condition and would be funded entirely from cash on hand. The tender offer was subject to a majority tender condition and Hart-Scott-Rodino clearance. [argenx Form 6-K (press release)](https://www.sec.gov/Archives/edgar/data/1697862/000110465926086760/tm2621326d1_ex99-1.htm)
3. 2026-05-06 Governance argenx shareholders approve CEO succession at annual meeting argenx said on 2026-05-06 that shareholders at its annual general meeting approved Karen Massey as executive director, and the board then appointed her chief executive officer. Co-founder Tim Van Hauwermeiren, CEO since 2008, became non-executive director and board chair. About 90.9% of share capital was represented, and all agenda items passed. [argenx Form 6-K (press release)](https://www.sec.gov/Archives/edgar/data/1697862/000110465926056296/tm2613815d1_ex99-1.htm)
4. 2026-01-05 Governance argenx announces CEO transition from Van Hauwermeiren to Massey On 2026-01-05 argenx announced that chief operating officer Karen Massey would become chief executive and executive director, and CEO Tim Van Hauwermeiren would become non-executive director and chairman, succeeding the retiring Peter Verhaeghe. The company said the changes were subject to shareholder approval at the 2026-05-06 annual general meeting. [argenx Form 6-K (press release)](https://www.sec.gov/Archives/edgar/data/1697862/000110465926000406/tm261773d1_ex99-1.htm)
5. 2025-11-18 Governance argenx shareholders approve revised remuneration policy argenx reported on 2025-11-18 that its extraordinary general meeting approved a revised remuneration policy, the only voting item. The policy passed with 95.67% of votes, with 91.1% of share capital represented at the meeting. The company announced the meeting on 2025-10-03 and said it had proposed adopting the revised policy there. [argenx Form 6-K (press release)](https://www.sec.gov/Archives/edgar/data/1697862/000110465925113712/tm2531632d1_ex99-1.htm)

## Pipeline

| Program | Indication | Stage |
|---|---|---|
| Vyvgart (efgartigimod) | Ocular myasthenia gravis | sBLA submitted to FDA [Source](https://www.sec.gov/Archives/edgar/data/0001697862/000169786226000034/a02earningspressreleaseq3.htm) |
| Vyvgart and Vyvgart Hytrulo | Pediatric generalized myasthenia gravis | sBLA accepted with priority review, PDUFA February 2027 [Source](https://www.sec.gov/Archives/edgar/data/0001697862/000169786226000034/a02earningspressreleaseq3.htm) |
| Vyvgart Hytrulo (efgartigimod SC) | Immune-mediated necrotizing myopathy (IMNM) | Phase 3 ALKIVIA positive, sBLA planned by year-end 2026 [Source](https://www.sec.gov/Archives/edgar/data/0001697862/000169786226000034/a02earningspressreleaseq3.htm) |
| Empasiprubart | Multifocal motor neuropathy | Phase 3 EMPASSION, topline December 2026 [Source](https://www.sec.gov/Archives/edgar/data/0001697862/000169786226000034/a02earningspressreleaseq3.htm) |
| FB102 (anti-CD122) | Celiac disease | Phase 2 positive, moving to phase 3 [Source](https://www.globenewswire.com/news-release/2026/10/08/3376936/0/en/index.html) |

Opinion · Devil's advocate

## Fact-check-o-meter

Some gaps

argenx's sales figures are consistent within its own release, but its trial messaging rounds off the misses

Vyvgart sales and profit in the third-quarter release match the interim statements in the same release. The gaps are in how trial news is framed: the quarterly update skips the Sjögren's futility stop, calls the myositis effect consistent across a subtype that missed significance, and names a celiac primary endpoint that differs from the one on ClinicalTrials.gov.

1. Press release vs filing · weight medium Quarterly update leaves out the Sjögren's trial stop **The company said:** "The story of argenx is one of continued innovation, growth and impact" [source](https://www.sec.gov/Archives/edgar/data/1697862/000169786226000034/a02earningspressreleaseq3.htm) **The record says:** Two weeks earlier, a 6-K exhibit announced that argenx "will discontinue the Phase 3 UNITY study of efgartigimod subcutaneous (SC) (efgartigimod alfa and hyaluronidase-qvfc) in adults with moderate-to-severe Sjögren's disease" because the IDMC "concluded that the UNITY study is unable to meet its primary endpoint." The October 22 third-quarter release, which lists Vyvgart's programs indication by indication, does not mention Sjögren's or UNITY. [source](https://www.sec.gov/Archives/edgar/data/1697862/000110465926114491/tm2627263d1_ex99-2.htm) **Our view:** The stop was disclosed promptly in its own filing, so this is an omission from the summary, not a hidden event. Still, a reader of the quarterly update alone would not learn that one of Vyvgart's expansion studies ended in futility this month.
2. Science · weight medium Myositis effect called consistent across a subtype that missed **The company said:** "Reported positive Phase 3 ALKIVIA results with consistent and clinically meaningful treatment effects observed across immune-mediated necrotizing myopathy (IMNM) and dermatomyositis (DM)" [source](https://www.sec.gov/Archives/edgar/data/1697862/000169786226000034/a02earningspressreleaseq3.htm) **The record says:** The August 17 topline 6-K shows the primary endpoint was met in the combined population (p=0.0011) and in IMNM (p=0.0048), but "In DM, a similar clinically meaningful improvement of 14.5 points (p=0.1093) was observed (51.51 vs 36.96), though statistical significance was not reached in this smaller cohort." The third-quarter release says only that argenx plans "to conduct an additional registrational study in DM." [source](https://www.sec.gov/Archives/edgar/data/1697862/000110465926097589/tm2623372d1_ex99-1.htm) **Our view:** The point estimates are similar, so "consistent" is defensible as a description of effect size. But the plan for a new DM trial follows a subtype result that did not reach significance (p=0.1093), and the quarterly update does not say why the extra study is needed. The near-term filing is IMNM only.
3. Science · weight medium Celiac release and trial registry name different primary endpoints **The company said:** "The primary endpoint was change from baseline in the ratio of villus height-to-crypt depth (Vh:Cd) at day 78 versus placebo" [source](https://www.sec.gov/Archives/edgar/data/1697862/000110465926114491/tm2627263d1_ex99-1.htm) **The record says:** The ClinicalTrials.gov record for the same study (NCT06982963), last updated November 18, 2025, lists one primary outcome: "Change from baseline in the VCIEL" at 78 days, with estimated enrollment of 100 and status still recruiting. The release treats VCIEL as a supporting measure that was "consistent with the primary endpoint" and reports 126 patients enrolled. The release gives p-values but no effect sizes for any measure. [source](https://clinicaltrials.gov/study/NCT06982963) **Our view:** This may be a stale registry entry rather than a switched endpoint; we cannot tell from public records. Either way, the readout is a histology measure in a controlled gluten challenge, not a real-world efficacy endpoint, and the numbers behind "clinically relevant" have not been shown. Phase 3 design will say more.
4. Legal and disclosure record · weight low No material litigation disclosed **The record says:** The 2025 Form 20-F states: "During the previous 12 months, there have not been any legal, governmental or arbitration proceedings (including any such proceedings which are pending or threatened of which we are aware) which may have, or have had in the recent past, significant effects on argenx and/or the Group's financial position or profitability." Note 26 adds that the company "is currently not facing any outstanding claims or litigation that may have a significant adverse impact." No securities litigation or enforcement disclosed in the latest annual filing. [source](https://www.sec.gov/Archives/edgar/data/1697862/000169786226000032/argx-20251231.htm) **Our view:** The record is clean. Patent and biosimilar challenges are listed only as general risk factors, not as pending cases.

Documents we compared

- [argenx Q3 2026 results press release (6-K Exhibit 99.1)](https://www.sec.gov/Archives/edgar/data/1697862/000169786226000034/a02earningspressreleaseq3.htm) 2026-10-22
- [argenx FB102 phase 2 celiac topline (6-K Exhibit 99.1)](https://www.sec.gov/Archives/edgar/data/1697862/000110465926114491/tm2627263d1_ex99-1.htm) 2026-10-08
- [argenx UNITY Sjögren's study update (6-K Exhibit 99.2)](https://www.sec.gov/Archives/edgar/data/1697862/000110465926114491/tm2627263d1_ex99-2.htm) 2026-10-08
- [argenx ALKIVIA phase 3 topline (6-K Exhibit 99.1)](https://www.sec.gov/Archives/edgar/data/1697862/000110465926097589/tm2623372d1_ex99-1.htm) 2026-08-17
- [argenx Annual Report on Form 20-F for 2025](https://www.sec.gov/Archives/edgar/data/1697862/000169786226000032/argx-20251231.htm) 2026-03-19
- [ClinicalTrials.gov NCT06982963 (FB102 celiac phase 2)](https://clinicaltrials.gov/study/NCT06982963) 2026-10-23

This is opinion. We compare the company's own announcements with its filings and the scientific record, and link every source. It is not an allegation of wrongdoing and not investment or legal advice. Legal items list only matters disclosed in filings or by courts and regulators. Checked Oct 23, 2026. Companies can respond through our [right of reply](https://aibio.space/reputation/#reply).

## Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open EURONEXT:ARGX on TradingView](https://www.tradingview.com/symbols/EURONEXT-ARGX/).

## SEC filings and registration

- **SEC name**: Argenx Se

- **CIK**: 1697862

- **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836)

- **US tickers**: ARGX (Nasdaq)

- **State or country of incorporation**: P7

- **Fiscal year ends**: December 31

- **Filer category**: Large accelerated filer

- **Business address**: INDUSTRIEPARK ZWIJNAARDE 7, ZWIJNAARDE

- **Phone**: 32 (9) 310 34 00

- **Shares outstanding**: 61,883,306 as of 2025-12-31 (20-F filed 2026-03-19)

- **Former names**: argenx N.V

### Recent filings (8-K and 6-K are the company's own announcements)

- [6-K](https://www.sec.gov/Archives/edgar/data/1697862/000169786226000034/a01coverpageforsecfilingq3.htm) filed 2026-10-22
- [6-K](https://www.sec.gov/Archives/edgar/data/1697862/000110465926116751/tm2627805d1_6k.htm) filed 2026-10-19
- [6-K](https://www.sec.gov/Archives/edgar/data/1697862/000110465926114491/tm2627263d1_6k.htm) filed 2026-10-08
- [6-K](https://www.sec.gov/Archives/edgar/data/1697862/000110465926111631/tm2626570d1_6k.htm) filed 2026-09-29
- [6-K](https://www.sec.gov/Archives/edgar/data/1697862/000114036126034700/ef20081196_6k.htm) filed 2026-08-27
- [6-K](https://www.sec.gov/Archives/edgar/data/1697862/000110465926097589/tm2623372d1_6k.htm) filed 2026-08-17
- [6-K](https://www.sec.gov/Archives/edgar/data/1697862/000110465926089796/tm2621858d1_6k.htm) filed 2026-08-03
- [6-K](https://www.sec.gov/Archives/edgar/data/1697862/000110465926086760/tm2621326d1_6k.htm) filed 2026-07-27

Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001697862), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.

Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update)

---
Source page: https://aibio.space/companies/argenx/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "argenx (ARGX) stock news, pipeline, cash and catalysts", 2026-10-31, https://aibio.space/companies/argenx/